Ramucirumab release date

On April 21, 2014, the U.S. Food and Drug Administration (FDA) approved ramucirumab as a single-agent treatment for patients with advanced gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma who have previously received fluoropyrimidine- or platinum-containing chemotherapy. It was subsequently approved for the treatment of patients with non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma. Sold under the trade name Cyramza. In 2015, the European Union approved the marketing of ramucizumab, believing that its benefits outweighed its risks. In March 2022, ramucirumab was approved by the National Medical Products Administration and sold under the trade name Ciranza, but it has not yet been approved by the National Medical Insurance Bureau to enter the ranks of medical insurance.